Skip to content

Interventions to Improve Non-communicable Disease Management During the Pandemic

A Cluster Randomised Controlled Trial to Evaluate the Effectiveness of Digital Health Interventions in Improving Non-communicable Disease Management During the Pandemic in Rural Pakistan

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05699369
Enrollment
1500
Registered
2023-01-26
Start date
2023-01-25
Completion date
2024-02-15
Last updated
2023-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, Noncommunicable Diseases

Keywords

digital health interventions, non-communicable diseases, cluster randomised trial, implementation science, resilience, Pakistan

Brief summary

This randomized controlled trial aims to implement and evaluate a comprehensive package of digital health interventions for integrated COVID-non-communicable diseases (NCDs) care to manage NCDs in primary care facilities in rural Pakistan. The main questions it aims to answer are 1) whether such interventions are effective; 2) how they were implemented; and 3) whether such interventions are cost-effective. 30 rural health centers in Punjab Province, Pakistan will be randomized into two groups. The intervention group will provide a comprehensive package of digital health interventions to connect patients, patient champions, and public health providers to improve the management of NCDs during the pandemic, including 1) providing training to health providers regarding an integrated NCD-COVID guideline; 2) using a smartphone app to improve NCD case management and linking with patient champions; and 3) employing telementoring platform to improve quality of care. Usual care will be provided in the control group. Researchers will compare the two groups to see if the systolic blood pressure can be controlled better in the intervention group at 10 months.

Interventions

Described in arm descriptions.

Sponsors

Association for Social Development, Pakistan
CollaboratorUNKNOWN
Canadian Institutes of Health Reesearch
CollaboratorUNKNOWN
University of Toronto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)

Masking description

The research team will mask the statisticians when data is presented and analyzed.

Eligibility

Sex/Gender
ALL
Age
25 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Reside in the catchment of selected rural health centers; * Provide informed consent; * Newly diagnosed of hypertension, i.e., having a baseline blood pressure reading (recorded from the second blood pressure reading using a validated electronic blood pressure machine) of more than 140/90 mmHg; or who is an existing hypertensive patient but with uncontrolled blood pressure with a baseline blood pressure over 140/90 mmHg; * Have a smartphone or can access a smartphone from a relative.

Exclusion criteria

* Patients having an acute cardiovascular event in the last three months, terminal disease, or other conditions that the rural health center staff determine that will make participation impossible.

Design outcomes

Primary

MeasureTime frame
Systolic blood pressure (mmHg) measured in the rural health centerAt 10 months

Secondary

MeasureTime frame
Number of consultations with RHC doctors, including both in-person and virtual consultationsDuring the 10-month intervention period
Systolic and diastolic blood pressureAt 6 months
All-cause mortality rateDuring the 10-month intervention period
Proportion of patients who have had at least three doses of COVID vaccinationsAt 10 months
Proportion of participants been admitted to district hospitals for any reasonsDuring the 10-month intervention period
Random blood glucose (mmol/L)At 10 months
Body mass index (BMI)At 10 months
Diastolic blood pressure (mmHg) measured in the rural health centerAt 10 months
Percentage of patients with controlled blood pressure measured below 140/90 mmHg for patients with hypertension but without diabetes, and below 130/80 mmHg for patients with diabetesAt 10 months

Countries

Pakistan

Contacts

Primary ContactMuhammad Khan, PhD
ccp@asd.com.pk(92 51) 2611230-3

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026